PDE4 inhibition at the crossroads of IBD and obesity

Laurent Peyrin-Biroulet, Sailish Honap
Nature Reviews Gastroenterology & Hepatology · Springer Nature · 2026-11-13 · DOI: 10.1038/s41575-026-01284-8

Аннотация

Nature Reviews Gastroenterology & Hepatology, Published online: 13 November 2026; doi:10.1038/s41575-026-01284-8 Obesity and inflammatory bowel disease are increasingly recognized as interconnected inflammatory and metabolic disorders. New insights into glucagon-like peptide-1 signalling highlight the role of phosphodiesterase 4 in energy balance. Although phosphodiesterase 4 inhibitors have previously been studied in inflammatory bowel disease, their potential to address both gut inflammation and obesity remains unexplored.

Читать у издателя →

Похожие статьи